Royalty Pharma Announces $1.14 billion Acquisition of Royalty Rights in cancer drug Xtandi from the University of California, Los Angeles (UCLA)

Los Angeles, CA and New York, NY - March 4, 2016 – Royalty Pharma Announces $1.14 billion Acquisition of Royalty Rights in cancer drug Xtandi from the University of California, Los Angeles (UCLA).

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.